Point72 Middle East FZE’s Enanta Pharmaceuticals ENTA Stock Holding History

Point72 Middle East FZE’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-14,028	Closed	-$132K	–	441
2023 Q4	$132K	Buy	14,028 +4,589	+49%	+$42.8K	﹤0.01%	1133
2023 Q3	$105K	Buy	+9,439	New	+$152K	﹤0.01%	1135
2023 Q2	–	Sell	-4,057	Closed	-$164K	–	1688
2023 Q1	$164K	Buy	+4,057	New	+$194K	0.01%	997

Other funds holding ENTA

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Point72 Middle East FZE's ENTA Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Enanta Pharmaceuticals (ENTA) in Q1 2024, closing a stake of 14,028 shares — an estimated $132K sold.

Point72 Middle East FZE first reported a position in ENTA in Q1 2023 and held it in 3 quarters. The position peaked at $164K in Q1 2023. 107 funds tracked by Wall St. Rank hold ENTA as of Q1 2024.

Point72 Middle East FZE reported no remaining Enanta Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Point72 Middle East FZE sold 14,028 Enanta Pharmaceuticals shares in Q1 2024, an estimated $132K.
Point72 Middle East FZE first reported a position in Enanta Pharmaceuticals in Q1 2023 and held it in 3 quarters.
Point72 Middle East FZE's Enanta Pharmaceuticals position peaked at $164K in Q1 2023.
107 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.